ERBB2 and breast neoplasm: In this study, we explored the effects of intratumor cellular heterogeneity for ERBB2 copy number and PIK3CAH1047R on the response to different types of HER2-targeting therapeutic strategies and changes in this heterogeneity during treatment in human breast tumors and patient-derived xenografts (PDXs).